Differences in Prevalence and Psychosocial Characteristics of Irritable Bowel Syndrome According to Rome III and Rome IV Criteria in Medical and Nursing Students
- Author:
Ji Hwan PARK
1
;
Hyeok Jun JEONG
;
Ka Eun LEE
;
Hong Sub LEE
;
Seung Jung YU
;
Jun Sik YOON
;
Eun Jeong CHOI
;
Jung Ho PARK
;
Ki Bae BANG
;
Ju Seok KIM
;
Yong Sung KIM
;
Author Information
- Publication Type:Original Article
- From:Journal of Neurogastroenterology and Motility 2024;30(4):491-500
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:In Korea, changes in the prevalence of irritable bowel syndrome (IBS) after the Rome IV update have not been extensively studied.The aim of this study is to compare the prevalence and psychosocial risk factors of IBS according to Rome III and Rome IV criteria in medical and nursing students.
Methods:From August 13, 2021 to October 22, 2021, participants were enrolled and surveyed online. The survey includes general and specific questions for disease diagnosis and regarding participants’ social and psychological characteristics using the 36-item short form survey, the Brief Encounter Psychosocial Instrument-Korean version, and the Hospital Anxiety and Depression Scale.
Results:In total, 338 medical students and 102 nursing students completed the survey. IBS was diagnosed in 78 students (17.7%) using Rome III criteria and in 51 students (11.6%) using Rome IV criteria. Significant differences in physical functioning score and severity score were observed between patients diagnosed using Rome IV criteria and patients diagnosed using Rome III criteria. Multiple logistic regression revealed that severity score (adjusted odds ratio = 1.01; 95% confidence interval: 1.00-1.21; P = 0.022) is the only predictor of IBS that differentiates Rome IV criteria from Rome III criteria.
Conclusions:Even after updating the Rome IV diagnostic criteria, the prevalence of IBS in medical and nursing students in Korea remained high.Patients who met the Rome IV criteria had more severe symptoms and lower quality of life than patients who met the Rome III criteria.
